8 citations
,
January 2025 in “Journal of Adolescent Health” In this retrospective cohort study, researchers found that persistent discontinuation of gender-affirming hormones among transgender adolescents was rare, mainly due to achieving gender expression goals or access issues, with very few reidentifying with their birth-assigned sex.
July 2023 in “The Journal of Clinical Endocrinology and Metabolism” This narrative review suggests that, after at least two years of gender-affirming hormone therapy, nonathletic transgender individuals tend to have physical performance levels similar to cisgender individuals, though more controlled research is necessary, particularly among trans athletes.
32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.
28 citations
,
October 2018 in “Clinical Obstetrics and Gynecology” This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.
9 citations
,
May 2024 in “Journal of Clinical & Translational Endocrinology” This review examines existing evidence on the efficacy and safety of gender affirming hormone therapy in relation to Gender Affirmation Surgery, but reports no new clinical results.